Skip to content

Akebia Therapeutics, Inc.

AKBA· NasdaqCore metricsCIK 1517022

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -12.34%
Market cap
$138.50M
277.66M shares
Filings
887
$36.90M
Q3 2026+47.5% FY25 yoy
-$14.35M
Q3 2026N/M FY25 yoy
-$11.46M
Q3 2026N/M FY25 yoy
-$17.20M
Q3 2026derivedN/M FY25 yoy
-$0.05
Q3 2026N/M FY25 yoy
$159.25M
Q3 2026+256.4% FY25 yoy
$138.50M
—
0.7×
6.8×
10.01%
—

Twelve months to Sep 30, 2026 · derived

Price

$0.498872.37%$1.3062past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$236.20MFY 2025
$335.00M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$236,196,000reported
FY 20242024-12-31$160,180,000reported
FY 20232023-12-31$194,623,000reported
FY 20222022-12-31$292,484,000 revisedreported
FY 20212021-12-31$211,650,000 revisedreported
FY 20202020-12-31$294,644,000 revisedreported
FY 20192019-12-31$335,001,000reported
FY 20182018-12-31$207,742,000reported
FY 20172017-12-31$181,227,000reported
FY 20162016-12-31$1,535,000reported
FY 20152015-12-31$0reported
FY 20142014-12-31$0reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2014—$162.00K$162.00K—20.37M sh+1,372.6%—

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Product revenue, net · FY2018 · $6.82MLicense, collaboration and other revenue · FY2018 · $200.92MFY2019Product revenue, net · FY2019 · $111.12MLicense, collaboration and other revenue · FY2019 · $223.88MFY2020Product revenue, net · FY2020 · $128.90MLicense, collaboration and other revenue · FY2020 · $166.41MFY2021Product revenue, net · FY2021 · $142.22MLicense, collaboration and other revenue · FY2021 · $71.36MFY2022Product revenue, net · FY2022 · $176.95MLicense, collaboration and other revenue · FY2022 · $115.54MFY2023Product revenue, net · FY2023 · $170.30MAuryxia · FY2023 · $170.30MLicense, collaboration and other revenue · FY2023 · $24.32MFY2024Product revenue, net · FY2024 · $152.18MAuryxia · FY2024 · $152.18MLicense, collaboration and other revenue · FY2024 · $8.00MFY2025Product revenue, net · FY2025 · $227.33MAuryxia · FY2025 · $181.54MVafseo · FY2025 · $45.79MLicense, collaboration and other revenue · FY2025 · $8.86M
LineFY2025ShareChange
Product revenue, net$227.33M96%+49.4%
Auryxia$181.54M77%+19.3%
Vafseo$45.79M19%—
License, collaboration and other revenue$8.86M3.8%+10.8%
Total$236.20M

From the 10-K filed Feb 26, 2026AKBA

Pharmaceutical preparations

Akebia Therapeutics, Inc. is the 79th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Akebia Therapeutics, Inc. · CIK 1517022 · Engraved from SEC EDGAR